Finansal

Tartışmalar Teknikler Tahmin Mevsimlik

İşletme giderleri (COGS hariç)'in CRISPR THERAPEUTIC

Yıllık veri

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

TTM

‪‪−520,00 M‬‬

‪‪−390,00 M‬‬

‪‪−260,00 M‬‬

‪‪−130,00 M‬‬

‪0,00‬

Dönem

Değer

Değişim

Değişim %

TTM

‪‪−339,95 M‬‬

+‪‪56,31 K‬‬

+‪0,02‬%

2024

‪‪−340,00 M‬‬

+‪‪33,53 M‬‬

+‪8,98‬%

2023

‪‪−373,53 M‬‬

+‪‪125,76 M‬‬

+‪25,19‬%

2022

‪‪−499,29 M‬‬

‪‪−21,71 M‬‬

‪−4,55‬%

2021

‪‪−477,59 M‬‬

‪‪−171,77 M‬‬

‪−56,17‬%

2020

‪‪−305,82 M‬‬

‪‪−75,23 M‬‬

‪−32,63‬%

2019

2018

2017

2016

2015

3 ay veri

Q2 '17

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−120,00 M‬‬

‪‪−90,00 M‬‬

‪‪−60,00 M‬‬

‪‪−30,00 M‬‬

‪0,00‬

Dönem

Değer

Değişim

Değişim %

Q4 '24

‪‪−86,68 M‬‬

‪‪−6,36 M‬‬

‪−7,92‬%

Q3 '24

‪‪−80,32 M‬‬

+‪‪4,91 M‬‬

+‪5,76‬%

Q2 '24

‪‪−85,23 M‬‬

‪‪−4,68 M‬‬

‪−5,81‬%

Q1 '24

‪‪−80,55 M‬‬

+‪‪9,30 M‬‬

+‪10,35‬%

Q4 '23

‪‪−89,85 M‬‬

+‪‪5,42 M‬‬

+‪5,69‬%

Q3 '23

‪‪−95,27 M‬‬

+‪‪8,27 M‬‬

+‪7,99‬%

Q2 '23

‪‪−103,54 M‬‬

+‪‪3,79 M‬‬

+‪3,53‬%

Q1 '23

‪‪−107,34 M‬‬

+‪‪2,59 M‬‬

+‪2,36‬%

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19

Q3 '19

Q2 '19

Q1 '19

Q4 '18

Q3 '18

Q2 '18

Q1 '18

Q4 '17

Q3 '17

Q2 '17